99 related articles for article (PubMed ID: 11711446)
1. Progress in, and future prospects for, the treatment of primary pulmonary hypertension.
Wilkins MR; Wharton J
Heart; 2001 Dec; 86(6):603-4. PubMed ID: 11711446
[No Abstract] [Full Text] [Related]
2. [Collagen diseases with pulmonary hypertension].
Endo H; Tanaka S; Sakai M
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Jun; 27(3):127-36. PubMed ID: 15291249
[No Abstract] [Full Text] [Related]
3. Therapy for primary pulmonary hypertension.
McCormack D
Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
[No Abstract] [Full Text] [Related]
4. Pulmonary arterial hypertension--the primary pulmonary hypertension syndromes.
Hey JC; Scharf SM
Isr Med Assoc J; 2003 Apr; 5(4):298-303. PubMed ID: 14509142
[No Abstract] [Full Text] [Related]
5. [Therapeutic management of porto-pulmonary hypertension. Complication of portal hypertension: how to treat pleuro-pulmonary complications?].
Sitbon O
Rev Mal Respir; 2004 Jun; 21(3 Pt 1):637-43. PubMed ID: 15292861
[No Abstract] [Full Text] [Related]
6. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
McLaughlin VV; Palevsky HI
Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
[TBL] [Abstract][Full Text] [Related]
7. Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.
Moriyama K; Uzawa K; Iijima T; Kotani M; Moriyama K; Ohashi Y; Satoh T; Yorozu T
J Clin Anesth; 2012 Sep; 24(6):487-9. PubMed ID: 22762976
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
Bildirici I; Shumway JB
Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
[TBL] [Abstract][Full Text] [Related]
9. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
Frost AE; Quiñones MA; Zoghbi WA; Noon GP
J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a patient with severe pulmonary hypertension due to perivalvular leakage at aortic and mitral positions after aortic and mitral valve replacement.
Miura T; Nishida H; Kawai A; Maeda T; Kurosawa H; Koyanagi H
Gen Thorac Cardiovasc Surg; 2008 Oct; 56(10):521-5. PubMed ID: 18854932
[TBL] [Abstract][Full Text] [Related]
11. Take a deep breath: understanding pulmonary arterial hypertension.
Beachem J; Litton K
Crit Care Nurs Q; 2014; 37(2):188-98. PubMed ID: 24595256
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of primary pulmonary hypertension].
Chaouat A; Weitzenblum E
Presse Med; 2002 Feb; 31(7):320-8. PubMed ID: 11899690
[TBL] [Abstract][Full Text] [Related]
14. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
[TBL] [Abstract][Full Text] [Related]
15. A 50-year-old woman with dyspnea, lower extremity edema, and volume loss of the right hemithorax.
Shostak E; Sarwar A
Chest; 2009 Aug; 136(2):628-632. PubMed ID: 19666764
[No Abstract] [Full Text] [Related]
16. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
Chin KM; Channick RN; de Lemos JA; Kim NH; Torres F; Rubin LJ
Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
[TBL] [Abstract][Full Text] [Related]
19. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
[TBL] [Abstract][Full Text] [Related]
20. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.
Maron BA; Bhatt DL; Nykiel M; Kinlay S; Waxman AB
Crit Pathw Cardiol; 2012 Mar; 11(1):40-2. PubMed ID: 22337220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
